Clinical Case: 6-Week-Old With Prolonged Jaundice and Clay-Coloured Stools — Biliary Atresia for NEET PG

Version 1.0 — Published May 2026

The case

A 6-week-old male infant is brought to the pediatric outpatient department of a tertiary hospital in Bengaluru by his parents with persistent yellow discolouration of the eyes and skin. He was born at 39 weeks by normal vaginal delivery, birth weight 2.9 kg, Apgar 8 and 9 at 1 and 5 minutes, exclusively breastfed since day 1. Jaundice was first noticed by the family on day 3 of life; the visiting paediatrician at their suburban clinic assured them this was "normal breast-milk jaundice" and asked them to continue feeding and bring the baby back if jaundice worsened. The baby was discharged from the birth hospital on day 4 without a measured bilirubin.

The jaundice never resolved. Over the past 3 weeks the parents noticed that the stools had become progressively paler — from the normal yellow-green seedy breastfed stool of the first week to a chalky white, putty-like, clay-coloured stool. The urine has been darker than expected, staining the diaper yellow-brown — the mother first noticed this around day 14 but attributed it to dehydration. The baby is feeding well at the breast every 2-3 hours, no vomiting, no fever, no lethargy, alert and active between feeds.

Birth history — full-term normal vaginal delivery at a private nursing home; no perinatal asphyxia, no NICU admission, no phototherapy. Maternal antenatal serology — non-reactive for HIV, HBsAg, VDRL; rubella IgG positive (immune); CMV not tested. No maternal fever or rash during pregnancy. No oligohydramnios. Maternal blood group O Rh-positive; baby A Rh-positive (no haemolytic risk).

Family history — first child of a non-consanguineous marriage; no family history of liver disease, neonatal deaths, or metabolic disorders. The father is a software engineer; the mother is a homemaker; middle-class urban family with good access to healthcare but a fragmented primary-care experience.

Development — age-appropriate; smiles socially, fixes and follows, head control beginning.

On examination — alert active infant, weight 4.2 kg (50th centile), length 54 cm, head circumference 38 cm (all on track). Temperature 36.9, pulse 138/min, RR 36/min, SpO2 98 percent on room air. Marked icterus — yellow staining of the sclerae, face, trunk, and palms-soles (Kramer stage 5 — suggests significant hyperbilirubinaemia regardless of cause). No pallor, no cyanosis. Anterior fontanelle 2 x 2 cm, soft, not bulging. No dysmorphism (rules against Alagille — no triangular facies, no posterior embryotoxon visible on slit-lamp later). No cataract (rules against galactosemia clinically — confirmed with reducing substances).

Abdomen — soft, non-distended. Hepatomegaly — liver palpable 4 cm below the right costal margin, firm in consistency, smooth surface, no nodularity. No splenomegaly (rules against severe haemolysis and storage disorders early on). No ascites. No abdominal distension. Per-rectal examination — pale putty-coloured acholic stool on the glove. Genitalia normal male; no inguinal hernia.

Cardiovascular and respiratory examinations unremarkable — no murmur (Alagille would have peripheral pulmonary stenosis; this rules it out provisionally). Neurological — age-appropriate tone, primitive reflexes intact, no opisthotonus (rules against kernicterus from severe unconjugated jaundice).

The pediatric resident initiates urgent work-up and refers the case to the on-call pediatric gastroenterology consultant with a working impression of conjugated hyperbilirubinaemia in a 6-week-old, biliary atresia until proven otherwise.

Initial assessment and the time-critical principle

The single most important clinical principle in this case is that any jaundice persisting beyond 14 days of life in a term neonate must have a measured conjugated bilirubin fraction — and if conjugated, the work-up must be completed and a surgical decision reached within 1-2 weeks. Every week of delay between 6 and 12 weeks of life halves the chance of a successful Kasai portoenterostomy. This is not a watch-and-wait scenario.

A — Airway: patent, no concerns. B — Breathing: RR 36/min, SpO2 98 percent on room air, no distress. C — Circulation: pulse 138/min (normal for age), capillary refill less than 2 seconds, peripheral pulses well-felt. D — Disability: alert, active, age-appropriate tone and movements. E — Exposure: marked icterus, hepatomegaly, acholic stools, normal genitalia, no rash, no bruising.

Tier 1 investigations (same day)

• Total bilirubin — 9.8 mg/dL; direct (conjugated) bilirubin 6.4 mg/dL (65 percent of total — strongly pathological); indirect 3.4 mg/dL
• AST — 180 U/L (raised); ALT — 210 U/L (raised)
• ALP — 720 U/L (markedly raised — typical of cholestasis in infants where ALP is normally high but this is more than 2x age-adjusted upper limit)
• GGT — 580 U/L (markedly raised, over 10x upper limit — strong predictor of biliary atresia; low or normal GGT would suggest PFIC types 1-2 or bile acid synthesis defects)
• Albumin — 3.8 g/dL (normal); total protein — 5.6 g/dL
• PT 14.2 sec, INR 1.3 (mildly prolonged — vitamin K malabsorption from cholestasis); corrects after IV vitamin K 1 mg administration
• CBC — Hb 11.6 g/dL, WBC 9,800/microL, platelets 285,000 (normal); peripheral smear normal (no haemolysis)
• Blood group — A Rh-positive; mother O Rh-positive (no ABO incompatibility concerning enough to explain prolonged jaundice)
• TSH — 3.4 mIU/L; T4 — 9.8 microg/dL (normal — rules out congenital hypothyroidism)
• TORCH IgM panel — toxoplasma negative, rubella negative, CMV IgM negative (IgG positive — passive maternal), HSV negative
• Urine routine — bilirubin POSITIVE (in cholestasis), urobilinogen reduced; no reducing substances (rules against galactosemia clinically — confirmed later with GALT activity); no leucocytes, no nitrites
• Urine culture — no growth (rules out UTI as a cause of cholestasis)
• Alpha-1 antitrypsin level — 165 mg/dL (normal range 90-200); phenotype PiMM (normal — rules out alpha-1 antitrypsin deficiency)
• Sweat chloride — 22 mmol/L (normal, less than 30 — rules out cystic fibrosis)
• Blood culture — no growth

Tier 2 imaging (within 24-48 hours)

• Fasting and post-feed abdominal ultrasound — performed by an experienced pediatric radiologist. Liver enlarged, parenchymal echogenicity mildly increased, surface smooth, no focal lesion. Triangular cord sign POSITIVE — an echogenic triangular fibrous remnant measuring 5.2 mm in thickness is seen anterior to the portal vein bifurcation at the porta hepatis (greater than 4 mm cut-off; specificity over 95 percent). Gallbladder — small, contracted, measuring 1.2 cm long axis, non-distensible, with irregular margins (ghost gallbladder) — fails to contract on post-feed scan. Common bile duct not clearly identified. Intrahepatic biliary radicles not dilated. No choledochal cyst. Spleen normal size. No polysplenia or asplenia (BASM syndrome ruled out). No ascites.
• Hepatobiliary iminodiacetic acid (HIDA) scan — performed after 5 days of phenobarbitone priming (5 mg/kg/day) to maximise hepatic tracer uptake. Tc-99m mebrofenin injection. Hepatic uptake is prompt and normal. At 24 hours, NO tracer activity is seen in the small bowel — consistent with complete extrahepatic biliary obstruction. This finding is sensitive but less specific than triangular cord; combined with positive triangular cord, the diagnosis is now strongly supported.

Tier 3 liver biopsy (within 1 week)

• Percutaneous liver biopsy under ultrasound guidance — sent for histopathology. Findings: portal tract expansion, bile ductular proliferation, bile plugs in canaliculi and ductules, portal tract oedema, early portal fibrosis. No giant-cell transformation (which would favour idiopathic neonatal hepatitis). No PAS-positive globules (rules against alpha-1 antitrypsin once more). Iron staining normal. The picture is classic for extrahepatic biliary obstruction with secondary cholestatic injury — biliary atresia.

Investigations confirm biliary atresia with high pre-operative confidence. The pediatric surgery team is consulted for urgent intraoperative cholangiogram and Kasai portoenterostomy.

The diagnostic algorithm — distinguishing biliary atresia from its mimics

NEET PG tests the prolonged neonatal cholestasis differential extensively. The structured approach is OBSTRUCTIVE vs HEPATOCELLULAR vs INFECTIVE vs ENDOCRINE with confirmatory features.

Differential diagnosis of prolonged neonatal cholestasis

Why our patient is biliary atresia

Nine features confirm it: (1) jaundice from day 3 of life that never resolved (persistent, not regressed), (2) progressive acholic stools (clay-coloured), (3) dark urine staining diaper, (4) firm hepatomegaly 4 cm below costal margin, (5) conjugated bilirubin 65 percent of total, (6) GGT 580 U/L (over 10x upper limit), (7) triangular cord sign 5.2 mm anterior to portal vein bifurcation, (8) ghost gallbladder failing to contract post-feed, (9) HIDA non-excretion at 24 hours despite phenobarbitone priming. Liver biopsy shows ductular proliferation with bile plugs and portal fibrosis — classic extrahepatic biliary obstruction pattern.

Diagnosis

Biliary atresia in a 6-week-old (42-day-old) male infant, exclusively breastfed, with conjugated hyperbilirubinaemia, acholic stools, positive triangular cord sign, non-excreting HIDA scan, and confirmatory liver biopsy showing ductular proliferation and bile plugs, planned for intraoperative cholangiogram and Kasai portoenterostomy at day 47-48 of life — within the under-60-day window for maximal success.

Management — Kasai portoenterostomy and supportive care

The treatment principle is restore biliary drainage as early as possible to preserve native liver function. The two surgical decisions are (1) the timing of the Kasai and (2) the decision to proceed straight to transplantation in late presentations.

Pre-operative preparation

• IV vitamin K 1 mg/dose for 3 days to correct coagulopathy (INR 1.3 on presentation, normalised after 2 doses)
• Fat-soluble vitamin supplementation — vitamin A 5,000 IU/day, vitamin D 800 IU/day, vitamin E 25 IU/kg/day, vitamin K 2.5 mg twice weekly post-operatively for life until cholestasis resolves
• Medium-chain triglyceride (MCT)-enriched formula if breastfeeding alternative is needed; MCTs bypass the lymphatic absorption pathway and do not require bile salts
• Pre-operative antibiotics — single dose of IV ceftriaxone 50 mg/kg at induction
• Cross-match 1 unit of packed red cells for the surgery (blood loss is usually small but cholestatic infants tolerate hypovolaemia poorly)
• Informed consent — staged disclosure: intraoperative cholangiogram first; if biliary atresia confirmed, Kasai portoenterostomy in the same operation; if a choledochal cyst is found instead, cyst excision with Roux-en-Y hepaticojejunostomy; if the porta hepatis is unfit for Kasai (rare, advanced cirrhosis) the family is counselled about primary transplantation

The Kasai procedure

Kasai portoenterostomy (Kasai hepatic portoenterostomy):

• Patient position — supine, right side elevated slightly
• Incision — right-sided transverse subcostal (extended midline for exposure if needed)
• Intraoperative cholangiogram — first step. If a gallbladder remnant is identified, it is cannulated and contrast is injected; non-filling of the extrahepatic biliary tree confirms biliary atresia. If the gallbladder is absent (10-20 percent), cholangiogram is not feasible and the surgeon proceeds based on macroscopic findings of the fibrous porta plate
• Excision of the atretic biliary tree — the fibrous remnant of the extrahepatic biliary tree (including the atretic gallbladder, common hepatic duct remnant, and porta plate) is mobilised and excised down to the porta hepatis at the level of the bifurcation of the portal vein
• Frozen-section biopsy of the transected porta plate — confirms the presence of residual ductules greater than 150 microm (which carry the bile drainage potential) — favourable prognostic sign
• Roux-en-Y jejunal limb — a 40-cm jejunal limb is fashioned from the proximal jejunum, brought up in a retrocolic position, and anastomosed end-to-side to the porta hepatis exposed transected fibrous porta
• Jejunojejunostomy — restores intestinal continuity 40 cm distal to the porta anastomosis
• Closure with drain placement in the subhepatic space
• Operating time — typically 3-4 hours
• Post-operative monitoring — NICU for 24-48 hours, NG decompression for 48-72 hours, IV antibiotics (ceftriaxone + metronidazole) for 7-10 days, gradual feeds starting with clear fluids on day 3-4

Post-operative care and bile flow assessment

• Day 0-3 — NICU monitoring, NG decompression, IV antibiotics, IV fluids, vitamin K
• Day 4-7 — gradual introduction of breast milk or MCT-enriched formula; stool colour monitored daily (return to yellow-green seedy stool is the earliest marker of successful bile drainage, often by day 7-10)
• Day 10-14 — discharge if bile-stained stool established, weight gain, no fever, drain removed
• Steroid pulse therapy — controversial; some centres use IV methylprednisolone 4 mg/kg/day tapering over 4-6 weeks post-Kasai to reduce cholangiopathy progression; evidence equivocal (the START trial 2014 showed no benefit; some Indian centres still use it for select cases)
• Prophylactic antibiotics — oral cotrimoxazole 5 mg/kg of trimethoprim component twice daily for 6-12 months to prevent ascending cholangitis through the Roux limb
• Ursodeoxycholic acid (UDCA) 15-20 mg/kg/day to improve bile flow and reduce cholestatic injury
• Fat-soluble vitamin supplementation lifelong until cholestasis resolves
• Bilirubin monitoring — total and direct bilirubin at 1 month, 3 months, 6 months post-Kasai. Clearance to normal (under 2 mg/dL by 3 months) predicts good native-liver survival; persistent jaundice (over 6 mg/dL at 3 months) signals failed Kasai and triggers transplant evaluation

When Kasai fails — liver transplantation

Indications for liver transplantation in biliary atresia:

• Failed Kasai — total bilirubin remains greater than 6 mg/dL at 3-6 months post-operatively
• Late presentation beyond 100 days, where Kasai is unlikely to succeed (some centres proceed directly to transplantation if presentation is over 120-150 days)
• End-stage liver disease — INR over 1.5 not corrected by vitamin K, albumin under 2.8 g/dL, synthetic dysfunction
• Recurrent uncontrollable cholangitis despite prophylactic antibiotics
• Intractable variceal bleeding from portal hypertension
• Hepatopulmonary syndrome or portopulmonary hypertension
• Failure to thrive despite optimal nutritional support

Living-related donor liver transplantation (LDLT) is the dominant model in India given the scarcity of deceased donors; centres like ILBS, Apollo, Medanta, AIIMS, and CMC Vellore now perform LDLT in infants weighing as little as 5-7 kg with 5-year survival approaching 85-90 percent.

Complications — short and long-term

Short-term

• Anastomotic bile leak — under 5 percent in experienced hands
• Wound infection — 5-10 percent
• Post-operative ileus — usually self-limiting
• Early cholangitis — 10-20 percent in the first month; treat aggressively with IV antibiotics

Medium-term

• Recurrent ascending cholangitis — 40-60 percent in the first year; bacterial translocation through the Roux limb; presents with fever plus deepening jaundice plus pale stools; blood cultures and broad-spectrum IV antibiotics
• Failed Kasai — bilirubin remains over 6 mg/dL at 3-6 months in 20-50 percent of cases
• Portal hypertension — develops in 60-70 percent of post-Kasai patients by age 5; surveillance endoscopy from age 2-3 years

Long-term

• Variceal bleeding — 10-30 percent; managed by band ligation and beta-blockers; rescue TIPS or transplant
• Ascites — manage with sodium restriction, spironolactone, paracentesis
• Hepatopulmonary syndrome — clubbing, hypoxaemia, intrapulmonary shunting; transplant indication
• Portopulmonary hypertension — needs early diagnosis (echocardiogram surveillance from age 5)
• Hepatocellular carcinoma — rare in childhood but reported; alpha-fetoprotein surveillance
• Need for transplant — overall, 50-60 percent of biliary atresia children require liver transplantation by age 20 even after successful Kasai

India-specific considerations

• Delayed referral from primary care is the single biggest preventable cause of late Kasai in India. The cultural and clinical assumption that "yellow babies" represent breast-milk jaundice or physiologic jaundice delays measured conjugated bilirubin testing by weeks. The Indian Academy of Pediatrics (IAP) and the Indian Society of Pediatric Gastroenterology, Hepatology and Nutrition (ISPGHAN) have campaigned for stool colour cards to be issued to every newborn at discharge — the Taiwan model where infant stool colour cards screen for biliary atresia at week 1 has reduced late Kasai by 70 percent and is being piloted in Kerala, Tamil Nadu, and Karnataka
• The 14-day rule — every primary-care physician should know that jaundice persisting beyond 14 days in a term baby (21 days in a preterm) demands a measured conjugated bilirubin — not reassurance
• NRC (Nutrition Rehabilitation Centre) referral pathway — biliary atresia is often picked up at NRC follow-up when failure to thrive becomes obvious; by this time the window for Kasai may have closed
• Limited centres performing Kasai — high-volume centres include AIIMS (Delhi), PGI (Chandigarh), NIMHANS, CMC Vellore, KEM (Mumbai), SGPGI (Lucknow), AIIMS (Bhubaneswar), Apollo (multiple cities), Medanta (Gurgaon). District hospitals should refer immediately rather than complete every test locally
• Cost considerations — Kasai procedure cost ranges Rs 1.5-3 lakh in private centres; covered under PMJAY (Pradhan Mantri Jan Arogya Yojana) for eligible families; transplant cost Rs 18-25 lakh for living-donor LDLT, increasingly accessible through PMJAY and state schemes
• High prevalence of CMV co-infection complicates the picture in Indian cohorts — CMV PCR on liver biopsy is recommended
• Stigma against surgery in newborns — families may hesitate, fearing surgical risk; clear communication that delay halves success is essential

How NEET PG tests biliary atresia

Seven recurring patterns.

Pattern 1 — The 14-day jaundice rule: Vignette gives a 3-week-old term baby with persistent jaundice; asks the next investigation. Measure total and conjugated (direct) bilirubin. A direct fraction greater than 1 mg/dL or greater than 20 percent of total confirms cholestasis and is NEVER physiological.

Pattern 2 — The triangular cord sign question: Vignette describes a 6-week-old with prolonged jaundice and acholic stools; asks the diagnostic ultrasound finding. Triangular cord sign — echogenic triangular fibrous remnant anterior to the portal vein bifurcation greater than 4 mm. Specificity over 95 percent for biliary atresia.

Pattern 3 — The HIDA scan question: Best second-line imaging when ultrasound is equivocal? Hepatobiliary iminodiacetic acid (HIDA) scan with phenobarbitone priming for 5 days; non-excretion of tracer into bowel within 24 hours suggests extrahepatic biliary obstruction.

Pattern 4 — The Kasai timing question: Best timing for Kasai portoenterostomy in biliary atresia? Within 60 days of life (8 weeks). Why? Success drops from 80 percent under 60 days to 50 percent at 60-90 days to 20 percent over 90 days because ongoing cholangiopathy destroys residual ductules.

Pattern 5 — The differential question: A 6-week-old with prolonged jaundice, NORMAL stool colour, hepatomegaly, raised GGT, family history? Alagille syndrome (look for triangular facies, butterfly vertebrae, posterior embryotoxon, peripheral pulmonary stenosis). A 4-week-old with vomiting, hepatomegaly, cataracts, E coli sepsis, urine reducing substances? Galactosemia. A 6-week-old with low GGT, severe pruritus? PFIC type 1 or 2.

Pattern 6 — The gold-standard question: Gold-standard diagnostic confirmation of biliary atresia? Intraoperative cholangiogram (with conversion to Kasai if confirmed). Liver biopsy is supportive (ductular proliferation, bile plugs) but not the gold-standard.

Pattern 7 — The post-Kasai complication question: Most common complication after Kasai portoenterostomy in the first year? Recurrent ascending cholangitis (40-60 percent; gut bacterial translocation through the Roux limb; prophylactic cotrimoxazole 6-12 months). When is transplant indicated? Failed Kasai (bilirubin over 6 mg/dL at 3-6 months), late presentation over 100 days, end-stage liver disease, intractable variceal bleeding, hepatopulmonary syndrome.

High-yield one-liners:

• Jaundice persisting beyond 14 days in a term neonate is pathological until proven otherwise
• Conjugated (direct) bilirubin greater than 1 mg/dL or greater than 20 percent of total confirms cholestasis — NEVER physiological
• Biliary atresia is the commonest surgical cause of neonatal cholestasis (25-40 percent)
• Acholic stools plus dark urine plus firm hepatomegaly plus raised GGT — classic biliary atresia tetrad
• Triangular cord sign greater than 4 mm anterior to portal vein bifurcation — specificity over 95 percent
• Ghost gallbladder — small, contracted, non-distensible, fails to contract post-feed
• HIDA scan non-excretion at 24 hours after phenobarbitone priming — suggestive but less specific
• Liver biopsy — ductular proliferation, bile plugs, portal fibrosis
• Intraoperative cholangiogram — gold-standard
• Kasai portoenterostomy ideally before 60 days (success 80 percent under 60 days, 20 percent over 90 days)
• Recurrent cholangitis is the commonest post-Kasai complication; prophylactic cotrimoxazole 6-12 months
• 50-60 percent of biliary atresia children will need liver transplant by age 20
• Alagille — triangular facies, butterfly vertebrae, posterior embryotoxon, peripheral pulmonary stenosis, JAG1
• Stool colour cards at birth discharge — being piloted in India to reduce late Kasai

Frequently Asked Questions

When is neonatal jaundice considered pathological and what triggers an urgent cholestasis work-up?

Physiological jaundice in a term neonate appears after 24 hours, peaks at day 3-5 (unconjugated bilirubin under 12 mg/dL), and resolves by day 14. Breast-milk jaundice may extend mildly to 4-6 weeks but remains unconjugated. Any jaundice that (1) starts before 24 hours of life, (2) lasts beyond 14 days in a term baby or 21 days in a preterm baby, (3) has total bilirubin over 17 mg/dL in a term baby, (4) shows a rapid rise greater than 5 mg/dL per day, OR (5) has a conjugated (direct) fraction greater than 1 mg/dL when total is under 5 mg/dL, or greater than 20 percent of total when total is over 5 mg/dL — is pathological and triggers an urgent cholestasis work-up. The conjugated fraction is the single most important number; conjugated hyperbilirubinaemia is NEVER physiological and demands rapid evaluation for biliary atresia within days, not weeks. NEET PG repeatedly tests the 14-day cut-off and the conjugated fraction threshold.

What is the differential diagnosis for prolonged neonatal cholestasis and how is biliary atresia distinguished?

Prolonged neonatal cholestasis (conjugated hyperbilirubinaemia after 14 days) has a structured differential. Obstructive (extrahepatic) — biliary atresia (most common surgical cause, 25-40 percent of all neonatal cholestasis), choledochal cyst, inspissated bile syndrome, gallstones, neonatal sclerosing cholangitis. Hepatocellular (intrahepatic) — idiopathic neonatal hepatitis, alpha-1 antitrypsin deficiency (most common metabolic cause in West, less common in India), Alagille syndrome (paucity of interlobular bile ducts plus characteristic facies, butterfly vertebrae, posterior embryotoxon, peripheral pulmonary stenosis, JAG1 mutation), progressive familial intrahepatic cholestasis (PFIC types 1-6), galactosemia, tyrosinemia, hereditary fructose intolerance, Niemann-Pick C, bile acid synthesis defects. Infective — TORCH (toxoplasma, rubella, CMV, herpes), syphilis, HIV, sepsis, urinary tract infection, viral hepatitis. Endocrine — hypothyroidism, hypopituitarism. The discriminating features for biliary atresia are pale clay-coloured (acholic) stools, dark urine staining diapers, hepatomegaly with firm consistency, conjugated fraction over 20 percent of total, raised GGT (over 10x), triangular cord sign on USG (echogenic fibrous remnant anterior to portal vein bifurcation greater than 4 mm), absent or contracted gallbladder, non-excretion of tracer into bowel on HIDA scan within 24 hours, and ductular proliferation with portal fibrosis on liver biopsy. Intraoperative cholangiogram remains the gold-standard diagnostic confirmation.

Why is Kasai portoenterostomy ideally performed before 8 weeks of age and what are the success rates by timing?

The Kasai portoenterostomy (hepatoportoenterostomy) is the first-line surgical procedure for biliary atresia, in which the atretic extrahepatic biliary tree is excised down to the porta hepatis and a Roux-en-Y jejunal limb is anastomosed to the exposed transected fibrous porta to restore biliary drainage via residual microscopic ductules. Success — defined as bilirubin normalisation and bile flow restoration — depends critically on age at surgery because ongoing cholangiopathy progressively destroys the residual ductules and leads to irreversible biliary cirrhosis. Published series consistently show bile drainage in approximately 80 percent of patients operated before 60 days, 50-60 percent between 60-90 days, and only 20-25 percent after 90 days. Native-liver survival at 10 years is 50-60 percent if Kasai is performed before 60 days, dropping to 10-20 percent if after 90 days. The 8-week (56-day) target is the universally accepted cut-off in Indian and international guidelines (NASPGHAN, ESPGHAN). NEET PG tests the timing-of-Kasai question every paper — the most common option-set asks the upper age limit for a meaningful Kasai (answer: 8 weeks or 60 days, with rapidly declining success beyond). Delayed referral from primary care misclassifying prolonged jaundice as physiologic or breast-milk jaundice is the single biggest preventable cause of late Kasai in India.

What investigations are needed in suspected biliary atresia and which is the gold-standard?

The work-up is staged and time-critical. Tier 1 (within 24-48 hours of suspicion) — total and direct bilirubin (conjugated greater than 1 mg/dL or 20 percent of total confirms cholestasis), AST, ALT, ALP, GGT (very high in biliary atresia, often over 10x upper limit), albumin, PT/INR (rule out coagulopathy from vitamin K malabsorption), CBC, blood group, urine and blood cultures, urine for reducing substances (galactosemia), TORCH IgM panel, TSH and T4 (hypothyroidism), alpha-1 antitrypsin level and phenotype, sweat chloride if cystic fibrosis suspected, and a stool colour card observation (acholic stools confirmed by parent and clinician). Tier 2 — fasting and post-feed abdominal ultrasound for triangular cord sign (echogenic anterior portal triangle greater than 4 mm; specificity over 95 percent), absent or non-distended (less than 1.5 cm) gallbladder, polysplenia or asplenia (BASM — biliary atresia splenic malformation syndrome), and to exclude choledochal cyst. Hepatobiliary iminodiacetic acid (HIDA) scan with phenobarbitone pre-treatment for 5 days — non-excretion of tracer into the bowel within 24 hours is highly suggestive of biliary atresia (sensitive but less specific than triangular cord sign). Tier 3 — percutaneous liver biopsy showing ductular proliferation, bile plugs, portal tract oedema, and progressive fibrosis (sensitivity 80-90 percent). The gold-standard remains the intraoperative cholangiogram with on-table conversion to Kasai portoenterostomy if biliary atresia is confirmed. Delaying surgery to complete every Tier 1-3 test is a common mistake — a clear clinical picture plus triangular cord plus HIDA non-excretion warrants prompt surgical referral.

What is the long-term follow-up after Kasai portoenterostomy and when is liver transplantation indicated?

After a successful Kasai, ongoing surveillance addresses three threats — cholangitis, portal hypertension, and progressive native-liver failure. Recurrent ascending cholangitis affects 40-60 percent of post-Kasai patients in the first year (gut bacteria translocating through the Roux limb) — every febrile episode warrants blood cultures and broad-spectrum IV antibiotics (piperacillin-tazobactam or meropenem). Long-term prophylactic cotrimoxazole or oral cephalosporins for 6-12 months reduces recurrence. Portal hypertension manifests with splenomegaly, varices (10-30 percent develop bleeding by age 5), and ascites — surveillance endoscopy is offered at age 2-3 years and as needed. Fat-soluble vitamin supplementation (A, D, E, K) is mandatory in cholestatic infants. Growth, nutrition, and developmental milestones are monitored. Liver transplantation is indicated when Kasai fails to clear jaundice (bilirubin remains greater than 6 mg/dL at 3-6 months post-op), in late presentations beyond 100 days where Kasai is unlikely to succeed, for end-stage liver disease with synthetic dysfunction (INR over 1.5 not corrected by vitamin K, albumin under 2.8 g/dL), recurrent uncontrollable cholangitis, intractable variceal bleeding, or hepatopulmonary syndrome. Transplant outcomes in well-equipped Indian centres (AIIMS, ILBS, Medanta, CMC Vellore, Apollo) now approach 85-90 percent 5-year survival, comparable to international benchmarks. Living-related donor transplant is the dominant model in India given deceased-donor scarcity. NEET PG tests both the Kasai-first principle and the failed-Kasai indication for transplant.

---

Written by: NEETPGAI Editorial Team Reviewed by: Pending SME Review Last reviewed: May 2026